Skip to main content
. 2022 Oct 14;107(1):80–86. doi: 10.1159/000526962

Table 1.

Demographic characterization of the study population (n = 14)

N (%) Mean (SD)
Age, years 73.9 (8.8)
Sex
 Male 11 (78.6)
 Female 3 (21.4)
CCI 10.1 (1.6)
ECOG performance status 0.8 (0.7)
Second-line therapy 11 (78.6)a
Bisphosphonate therapy 2 (14.3)

CCI, Charlson Comorbidity Index.

a

All received gemcitabine/cis-platin as first-line therapy.